increased heart rate on semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events – REGENHEALTHSOLUTIONS (RHS) GLP-1 Agonists and Heart Rate

Clinical research shows that this can start as early as 8 to 12 weeks after the last dose

PR Newswire 2025, "Palatin reports positive appetite suppression results from Phase 2 obesity study of MC4R agonist bremelanotide and tirzepatide"

However, long-term use should be evaluated based on individual health conditions, metabolic goals, and tolerance, especially when considering sustainability and dependency

For example, combining alcohol feeding with a high-fat diet (with fat accounting for 25% of the caloric intake) in rats for 30 days can lead to significant liver fibrosis ( Lactobacillus species ( However, the TF model has several limitations